Ainos, Inc. (AIMD) Stock Analysis & Investment Frameworks
Ainos, Inc. (AIMD) stock analysis on Invetso. Review Ainos, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Ainos, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Ainos, Inc. Key Financial Metrics
- Market Cap: $6.50M
- Revenue: $124157.00
- ROE: -217.50%
- ROIC: -80.51%
- Dividend Yield: N/A
About Ainos, Inc.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Ainos, Inc. Investment Frameworks
Invetso analyzes Ainos, Inc. (AIMD) across the following frameworks:
- Ainos, Inc. 10Y Growth Potential
- Ainos, Inc. Scenario Analysis
- Ainos, Inc. Risks & Opportunities
- Ainos, Inc. Economic Moat
- Ainos, Inc. Business Model
- Ainos, Inc. Management
- Ainos, Inc. SWOT Analysis
- Ainos, Inc. Porter's 5 Forces
- Ainos, Inc. PESTLE Analysis
- Ainos, Inc. ESG Analysis